section (i): brief account of...
Post on 10-Mar-2020
10 Views
Preview:
TRANSCRIPT
321
Section (i): Brief account of Pericalcitol
Pericalcitol (PCL) is the analog of 1,25-dihydroxyergocalciferol, the active form of vitamin
D2. Chemically, it is 19-nor-1,25-(OH)2-vitamin D2 or 19-nor-1,25-dihydroxyvitamin D2, with
the empirical formula of C27H44O3, which corresponds to a molecular weight of 416.64. PCL
is chemically designated as 19nor-1α,3β,25-trihydroxy-9,10-secoergosta-5(Z),7(E),22(E)-
triene and has the following structural formula:
PCL is a white, crystalline powder. PCL is marketed by Abbott Laboratories under the trade
name Zemplar. Zemplar Capsules (paricalcitol) are indicated for the prevention and treatment
of secondary hyperparathyroidism associated with chronic kidney disease (CKD) Stage 3 and
4, and CKD Stage 5 patients on hemodialysis (HD) or peritoneal dialysis (PD). Like 1,25-
dihydroxyergocalciferol, PCL acts as an agonist for the vitamin D receptor and thus lowers
the blood parathyroid hormone level.
PCL, the active ingredient in Zemplar Capsules, is a synthetically manufactured analog of
calcitriol, the metabolically active form of vitamin D. Zemplar is available as soft gelatin
capsules for oral administration containing 1 µg, 2 µg or 4 µg of PCL.
322
PCL drug substance and PCL injection drug product is official in US pharmacopeia
[1]. There is an article reported for stability indicating assay of PCL in injection dosage form
[2]. There are few assays reported in the literature for the determination of PCL determination
in biological fluids. An LC-radioreceptor assay [3] and HPLC-MS/MS [4] were applied in
pharmacokinetic studies. The former is applied to evaluate the effect of hemodialysis on the
pharmacokinetics of PCL; the latter evaluated the effect of omeprazole on the
pharmacokinetics of paricalcitol in healthy subjects.
However, there are no studies describing quantification methods for PCL and its
impurities in its pharmaceutical form, Zemplar® (paricalcitol) capsules.
There is no known impurity listed in PCL USP monograph. In PCL injection USP
Monograph, a total nine degradants are listed named as related compound A , B, C, D, E, F,
G,H and I. No structures are revealed for these listed impurities by USP. Out of nine
degradants, related compound A and related compound B are given as oxidative degradants
and remaining seven related compounds C, D, E ,F, G, H and I are given as acid degradants.
Reverse phase HPLC method available in USP for the related substances of PCL is useful for
injectable formulation as well as for drug substance. This method is found to be not suitable
for the related substances estimation in oil based capsule formulation due to placebo
interference of Cremophor EL peaks which are present in formulation. Sample solutions were
found to be turbid when the diluent (water : acetonitrile in 50 : 50 v/v ratio) suggested in USP
is used for oil based capsule formulation due to formation of emulsion. So far to our present
knowledge, no validated stability indicating HPLC method for the determination of related
substances of PCL in oil based hard gelatin capsule formulation is available in literature.
This prompted the author to develop stability indicating HPLC methods for the assay
and impurities of PCL in oil based capsules formulation. This chapter describes development
and validation of a stability indicating methods for assay and impurities.
339
Section (iii): Stability Indicating HPLC method for impurities of Paricalcitol
Capsules.
This section reports the various aspects relating to the development and
validation of stability indicating HPLC method for impurities in Paricalcitol (PCL)
capsule dosage form.
1. Experimental
1.1. Chemicals
PCL capsules are formulated in Dr Reddy’s laboratories Ltd, Hyderabad, India.
The reference standard of PCL is supplied by USP and standard is supplied by Dr.
Reddy’s laboratories limited, Hyderabad, India. The HPLC grade acetonitrile, ethanol,
dichloromethane, n-Hexane, isopropyl alcochol and analytical grade NaOH, HCl,30%
hydrogen peroxide are purchased from Merck, Darmstadt, Germany. High purity water
is prepared by using Milli Q Plus water purification system (Millipore, Milford, MA,
USA). The chemical names and structures of PCL is as shown below.
1.2. Determination of appropriate UV wavelength
The suitable wavelength for the determination of PCL and its impurities is
identified by taking the overlay spectra from 200–400 nm of all impurities and PCL
from PDA detector.
1.3. Instrumentation and chromatographic conditions
Waters HPLC System with a photo diode array detector is used for the
method development and force degradation studies. The HPLC system used for method
validation is waters HPLC system with diode array detector and Agilent 1100 series LC
system with variable wavelength detector (VWD). The data is monitored and processed
by using waters Empower Networking Software. The chromatographic column used is
an Inertsil Silica, 250mm x 4.6 mm column, with 3.0µ particle size. The
chromatographic condition follows a gradient program consisting of mixture of n-
Hexane, ethanol, and dichloromethane in the ratio of 900:30:30 v/v as mobile phase A
and of mixture of n-Hexane, ethanol, dichloromethane and isopropyl alcohol in the ratio
of 900:40:120:40 v/v as mobile phase B. The gradient program is : Time/% Mobile
phase B is 0.0/0, 18/0, 40/100, 70/100, 75/0, 85/0. The flow rate of the mobile phase is
1.5 ml min-1
. The column temperature is maintained at 30ºC and the detection
wavelength is 262 nm. The injection volume is 500µl.
340
1.4. Diluent: n-Hexane is used as diluent.
1.5. Preparation of PCL diluted standard solution:
An accurately measured amount of 1ml of USP Paricalcitol RS ( each ml
contains about 508 µg of PCL per ml) is transferred into a 50 mL dry volumetric flask.
The volume made up with ethanol and mixed well to obtain a standard stock solution of
about 10 µg of PCL per ml. 2ml of the stock solution is then diluted to 50 ml with ethanol
and mixed well. 5ml of this solution is then diluted to 100 ml with n-hexane to obtain a
standard preparation of about 0.02 µg of PCL per ml. The specimen chromatogram of
diluent and PCL diluted standard solution is shown in fig.6.3.1.
1.6. Test Preparation for PCL pharmaceutical formulations:
30 capsules of PCL capsules (hardgelatin) are weighed (W1) and the contents are
emptied by cutting with a sharp blade and then squeezing each capsule without loss of
material into a 50 ml beaker. The empty shells are washed with dichloromethane and
dried at room temperature. The empty capsule shells are then weighed (W2). Average
weight of contents of capsules are calculated by subtracting W2 from W1. Then the
medicament, which is squeezed already from capsules, equivalent to 20 µg of PCL is
transferred into a 10 ml volumetric flask. The contents of the flask is then diluted up to
the volume with diluent and shaken vigorously for 5 minutes. The resultant clear solution
is used for injection. Placebo sample is prepared in the same way by taking the placebo
equivalent its weight present in a test preparation. The specimen chromatogram of
placebo and test samples is shown in fig.6.3.2 and 6.3.3.
341
Fig 6.3.1: Specimen chromatograms of diluent and PCL diluted standard.
Fig 6.3.2: Specimen chromatogram of placebo for PCL capsules.
Diluent
Placebo
Diluted standard
342
Fig 6.3.3: Specimen chromatogram of PCL capsules.
343
1.7. Specificity:
Regulatory guidances in ICH Q2A, Q2B, Q3B and FDA 21 CFR section 211,
require the development and validation of stability-indicating impurities method for all
pharmaceutical dosage forms. However, the current guidance documents do not indicate
detailed degradation conditions in stress testing. The forced degradation conditions,
stress agent concentration and time of stress, are found to effect the % degradation.
Preferably not more than 20% is recommended for active materials to make the right
assessment of stability indicating nature of the chromatographic methods. Optimisation
of such stress conditions which can yield not more than 20% degradation is based on
experimental study. Chromatographic runs of placebo solution and samples subjected to
force degradation are performed in order to provide an indication of the stability
indicating properties and specificity of the method. The stress conditions employed are
acid, base, neutral and oxidant media, moisture, heat and light. After the degradation
treatments are completed, the samples are allowed to equilibrate to room temperature,
neutralized with acid or base (as necessary), and diluted with diluent to get the working
concentrations equivalent to test preparation. The samples are analyzed against a freshly
prepared control sample (with no degradation treatment) and evaluated for peak purity
by using photo diode array detector. Specific conditions are described below.
1.7.1. Placebo (excipients) interference:
Placebo solutions are prepared by taking the weight of placebo approximately
equivalent to its weight in the sample as described in the test preparation for PCL
capsules dosage form.
1.7.2. Effect of acid hydrolysis
Medicament equivalent to 20µg is treated with 0.2 ml of 0.5N ethanolic HCl and 2
ml of diluent. The solution is heated at 60°C for 1 hour. The resulting solution is diluted
to 10 ml with diluent to obtain a solution having final concentration of drug at about 2
µg ml-1
.
1.7.3. Effect of base hydrolysis
Medicament equivalent to 20µg is treated with 0.5 ml of 0.5N ethanolic NaOH
and 2 ml of diluent. The solution is heated at 60°C for 15 hours. The resulting solution is
344
diluted to 10 ml with diluent to obtain a solution having final concentration of drug at
about 2 µg ml-1
.
1.7.4. Effect of oxidation
Medicament equivalent to 20µg is treated with 0.2 ml of 6% H2O2 in ethanol and 2
ml of diluent. The solution is heated at 60°C for 3 hours. The resulting solution is diluted
to 10 ml with diluent to obtain a solution having final concentration of drug at about 2
µg ml-1
.
1.7.5. Effect of moisture and heat
To evaluate the effect of moisture and heat, PCL medicament is distributed as thin
layer over two glass plates. One plate is then exposed to 25ºC/90% relative humidity for
7 days. Similarly another plate is exposed in an oven at 60ºC for 48 hours. Then, both
the samples are subjected to sample preparation using diluents as described in test
preparation.
1.7.6. Effect of UV and visible light
To study the photochemical stability of the drug product, Paricalcitol medicament
is exposed to 1200 K Lux of visible light and 200 W h/ m2 of UV light by using photo
stability chamber. After exposure the samples are subjected to sample preparation using
diluents as described in test preparation.
1.8. Method validation
1.8.1. Identification of RRT of potential degradants :
The Relative retention times(RRT’s) of 7 specified degradant impurities are summarized
in table 5.3.1.
Table 5.3.1. RRT of PCL specified degradants in new method.
S.No Name of the impurity RRT
1 Specified degradant 1 0.22
2 Specified degradant 2 0.25
3 Specified degradant 3 0.26
4 Specified degradant 4 0.64
5 Specified degradant 5 0.67
6 Specified degradant 6 1.05
345
7 Specified degradant 7 1.16
Method validation is performed using stressed samples and or with PCL due to lack of
availability of standards for the specified degradants.
1.8.2. Precision
Precision (intra-day precision) of the impurities method is evaluated by using the
neutralised acid stressed sample as it contains 6 specified degradants except specified
degradant 6. The acid stressed sample is injected six times into the developed
chromatographic conditions described above. % of impurities are calculated against a
qualified PCL standard. RSD is then calculated for % of impurities individually obtained
for injections. The inter-day precision is also evaluated by six different samples by
spiking PCL on placebo matrix at 1% level. The intermediate precision (inter day
precision) of the method is also evaluated using different HPLC system and different
HPLC column on different day in the same laboratory.
1.8.3. Limits of Detection (LOD) and Limit of Quantification (LOQ)
The LOD and LOQ for PCL are determined at a signal-to-noise ratio of 3:1 and
10:1, respectively, by injecting a series of dilute solutions with known concentrations.
LOD and LOQ of each individual specified degradants are not estimated due to lack of
impurity standards. Precision study is also carried out at the LOQ level by injecting six
individual preparations of PCL spiked on placebo and % RSD is calculated.
1.8.4. Linearity
Linearity for PCL diluted standard is estimated by diluting stock solutions to the
required concentrations. The solutions are prepared at different concentration levels from
LOQ to 200% of the specification concentration level (1%) for PCL. The solutions are
then injected into the chromatographic conditions developed. The data of peak area
versus concentration is subjected to least-square regression analysis.
1.8.5. Accuracy
A study of recovery of PCL from placebo is conducted. Samples are prepared by
spiking PCL on placebo at different spike levels starting from LOQ to 150% of the
346
specification level(1%). Sample solutions are prepared in triplicate for each spike level
as described in the test preparation and injected into the chromatographic conditions
developed. The % recovery is then calculated against PCL diluted standard and
compared against the known amounts spiked.
1.8.6. Robustness
To determine the robustness of the developed method, experimental conditions
are deliberately altered and the elution patterns, resolution between PCL and its
impurities are evaluated. Stressed sample from acid degradation and oxidation
degradation is mixed for robustness evaluation purpose as together they produce all the
specified degradants. The effect of flow rate is studied at 1.5 ± 0.2 ml min-1.
The effect of
the column temperature is studied at 30ºC ± 3ºC. The effect of the percent organic
strength for both mobile phase A and mobile phase B is studied by varying by −10 to
+10% while other mobile phase components are held constant.
1.8.7. Solution stability and mobile phase stability
The stability of PCL and its impurities in solution for the impurities method is
determined by leaving test preparation of PCL capsules in a tightly capped volumetric
flask at room temperature on bench top and by measuring the amounts of impurities at
different intervals. The stability of mobile phase is also determined by analysing freshly
prepared solution of PCL capsules for 5 days by using the same mobile phase during the
study period.
2. Results and discussion
2.1. Determination of suitable wavelength
The UV spectrum of PCL and all its known impurities were extracted in PDA
detector from 200-400 nm and is illustrated in fig.6.3.4. The spectrum shows three
absorption maxima which can give a good sensitivity for the all impurities of PCL. The
third absorption maxima observed at 262 is found to be optimum as at other two
maxima, placebo is having interference for 0.22, 0.25 and 0.26 RRT degradants.
347
Fig 6.3.4: UV Spectra of Paricalcitol and its impurities.
348
2.2. Optimization of chromatographic conditions
The HPLC procedure is optimized with a view to develop a stability indicating
impurities method for estimation of impurities of PCL in oil based capsules formulation. PCL
related substances method is available in USP for PCL Injection, which is having the nine
degradants. Out of nine degradants, 7 are due to the acid stress (5 major and 2 minor) and
two degradants due to peroxide stress. RRT has been captured for all nine degradants in USP
method. However, no chemical names, structures are given in USP for these degradants. No
standards are supplied by USP for these impurities. In the absence of chemical names and
structures, it was not possible to get the impurities standards from market. To develop the
impurities method for PCL oil based formulation, where in medicament liquid is filled into
hard gelatin capsules and sealed, initially attempts were made by using reverse phase
chromatographic conditions of the USP PCL injection method. PCL capsules formulations
are of very low dose, namely 1 µg, 2 µg and 4 µg per capsule. Due to very low concentration
of the drug present in the medicament, it is observed that a very high injection volume is
necessary. A minimum of 500µl injection volume is selected to get adequate method
sensitivity. Preliminary experiments are conducted to dissolve the excipients (mainly
medium chain triglycerides and cremophore EL) in acetonitrile. When placebo and
medicaments are dissolved in acetonitrile, it is observed that all placebo components are not
going into solution and some of excipients are found to be immiscible. The recovery of PCL
analyte is found satisfactory in acetonitrile, but due to presence of cremophore EL in
formulation, interference is observed at the retention time of PCL degradants. The
inconsistency of peaks is also observed due to excipient immiscibility in acetonitrile. Several
experiments are conducted to separate out the excipients peaks from degradants by
modifying the USP method gradient program and by changing the column, but without much
success, due to inconsistency of placebo peaks. Attempts are made in different combination
of other solvents like DMF, DMSO to selectively extract PCL from formulation, but studies
are not successful, as excipient peaks were still appearing at the RT of PCL and its
degradants in reverse phase method in all of the diluents. Studies revealed that the excipient
majorly responsible for interference is cremophor EL. Therefore, studies are conducted based
on the reported literature method to remove the cremophor EL from formulation by using
precipitation technique involving mercuric chloride in a reaction with cremophor EL to form
an insoluble complex in ethanol. The efforts made to
349
remove the cremophore EL from formulation based on above mentioned literature
method [5] were successful, but PCL is getting degraded during sample preparation.
Based on the above studies, it is felt necessary to change the chromatographic
method from reverse phase to normal phase. This is to resolve the main constraint of
excipient solubility and immiscibility with most of the polar solvents, as normal phase
chromatography allows use non polar solvents as diluents, where in medium chain
triglycerides and cremophore EL are completely soluble. Additionally, due to polarity
reversal, interference due to cremophore EL can be easily avoided, as it elutes early in
normal phase due to its non polar nature.
Studies are conducted using 250 x 4.6mm, silica column by changing the
selectivity of the mobile phase to achieve symmetrical peak shapes and adequate
separation of all degradants from excipient peaks. It is noticed that isocratic elution
methods are not suitable separate the degradant peaks. Therefore, experiments were
conducted with different combination of solvents as mobile phase A and mobile phase
B and also by changing different gradient programmes.
Finally a mixture of n-Hexane: ethanol: dichloromethane (In ratio of 90: 3: 3
v/v) as mobile phase A and mixture of n-Hexane: ethanol: dichloromethane: isopropyl
Alcohol in the ratio of 90 : 4 : 12 : 4 v/v as mobile phase B are found suitable with
adequate separation of all degradant peaks and avoiding interference. The optimum
gradient program (T/%B) is set as 0/0, 18/0, 40/100, 70/100, 75/0, 85/0.
Identification of RRT’s of degradants in the new method:
After the success in resolving the issue of excipient interference, a challenge
faced is to identify the RRT’s of the major degradants in the new normal phase method,
as the structures and standards are not available. Therefore, it is decided to collect the
fractions of all major degradation products in USP method and inject in newly
developed normal phase method to identify the RRT’s of the major degradants. PCL is
subjected to stress with peroxide and acid as per USP PCL injection related substance
method as given below.
350
Acid degradation solution 1 – for getting unknown related compound D, F, G and H
1.0 mL of USP Paricalcitol solution RS is taken into 10 ml volumetric flask and
1 mL of 0.1N HCl is added. The resultant solution is heated at 70°C for 2 hrs and
diluted to volume with diluent (acetonitrile : water in 50 : 50 ratio) and mixed.
Acid degradation solution 2 – for getting unknown related compound C.
0.5 ml of USP Paricalcitol solution RS is taken into 10 ml volumetric flask and
0.5 ml of 0.5N ethanolic HCl is added. The resultant solution is heated at 60°C for 90
minutes and diluted to volume with diluent ( acetonitrile : water in 50 : 50 ratio) and
mixed.
Oxidative degradation solution – for getting unknown related compound A and B
2.0 mg of PCL standard is accurately weighed and transferred into 5 ml
volumetric flask. 0.5 ml of ethanol and 0.5 mL of 50 % Hydrogen Peroxide solution is
added. The resultant solution is kept on bench top for 1 hour and diluted to volume with
diluent (50 % acetonitrile and 50 %water) and mixed.
A 500µL of injection volume of acid degradant solution 1, acid degradant
solution 2 and oxidative degradant solution are injected in PCL Injection USP method
using (Alltima C18, 250 x 4.6 mm, 5µm) as main column and (Altima C18, 75 x 4.6
mm, 5µm) as guard column with mobile phase containing a gradient mixture of solvent
A and B. A mixture of Milli Q Water and acetonitrile is used in 85:15 v/v as solvent A
and acetonitrile is used as solvent B. The gradient program is set as (T/%B) 0/35, 25/95,
45/95, 47/35, 60/35. The eluted compounds are monitored at 262nm.
Fractions of all major degradants (A,B,C,D,F,G,H) are collected based on the
RRT’s given in USP. As per USP PCL Injection method, unknown related compound
“E and I” forms in very less concentration. These compounds are not formed with the
specified degradation conditions and hence no fractions collected for these peaks. All
fractions of impurities are pooled and dried by hot air and reconstituted with
dichloromethane and then injected into newly developed normal phase method. Based
on the injections, RRT’S of the major degradants are identified in the in new method.
RRT comparison in USP PCL injection method and newly developed PCL capsule
method is summarized in table 6.3.2.
351
Table 6.3.2. Comparative RRT’s of degradants in USP and New method
Source Name RRT as per USP
Injection reverse
phase method
RRT as per
capsule normal
phase method
Oxidative
degradation
Unknown Related
compound-A
0.63 1.16
Oxidative
degradation
Unknown Related
compound-B
0.79 1.12
Acid degradation 2 Unknown Related
compound-C
0.89 1.05
Acid degradation 1 Unknown Related
compound-D
0.95 1.16
Acid degradation 1 Unknown Related
compound-E
1.32
( not forming)
Not applicable
Acid degradation 1 Unknown Related
compound-F
1.57 0.64
Acid degradation 1 Unknown Related
compound-G
1.66 0.64
Acid degradation 1 Unknown Related
compound-H
1.74 0.67
Acid degradation 1 Unknown Related
compound-I
1.79
(not forming)
Not Applicable
Thermal
degradation
Specified
degradant-1
Not Detected* 0.22
Thermal
degradation
Specified
degradant-2
Not Detected* 0.25
Thermal
degradation
Specified
degradant-3
Not Detected* 0.26
(* Not detected due to non-polar nature and also due to interference from cremophor EL)
In the new method of PCL Capsules, 3 new thermal degradants are also observed
in the PCL capsule formulation samples which are not possible to see in the USP
method. However, unknown compound A is co eluting with the unknown compound D
(1.16 RRT) and unknown compound F is co eluting with unknown compound G (0.64
RRT). Efforts made to separate them are not successful due to limitations of normal
phase. On the basis of the degradation study and stability data in capsule formulation, it
is observed that only four acid / oxidative degradants ( at RTT 0.64, RRT 0.67, RRT
1.05 and RRT 1.16 ) and 3 new thermal degradants (at RRT 0.22, RRT 0.25, RRT 0.26)
are present. Other degradants (like RRT 1.12) are not forming in capsule formulations
upon manufacturing and upon stability and hence not part of this present method study
352
further. The 3 new thermal degradants along with acid and oxidation degradants are
designated in the new method as given in table 6.3.3.
Table 6.3.3. RRT’s of specified degradants in new normal phase method.
S.No Name of the impurity RRT Nature of the Impurity
1 Specified degradant 1 0.22 Thermal degradant
2 Specified degradant 2 0.25 Thermal degradant
3 Specified degradant 3 0.26 Thermal degradant
4 Specified degradant 4 0.64 Acid degradant
5 Specified degradant 5 0.67 Acid degradant
6 Specified degradant 6 1.05 Acid degradant
7 Specified degradant 7 1.16 Oxidation degradant
The fractions of all the unknown impurities listed in USP are collected and subjected
to mass spectroscopic study to understand the possible structures. The data is
summarized in table 6.3.4.
Table 6.3.4. HRMS data of specified degradants of PCL.
USP name Impurities
Name RRT
(about)
Observed m/z
by HRMS
Observed
molecular
formula
Exact
Mass
[M]
Exact
Molecular
Formula
NA Specified
degradant-1 0.22
381.3141
[M+H]+
C27H41O 380.3141 C27H40O
NA Specified
degradant-2 0.25
381.3118
[M+H]+
C27H41O 380.3118 C27H40O
NA Specified
degradant-3 0.26
381.3129
[M+H]+
C27H41O 380.3129 C27H40O
Unknown
compound F
Specified
degradant-4 0.64
381.3140
[M-18]+
C27H41O 398.3140 C27H42O2
Unknown
compound G
Specified
degradant-4 0.64
381.3138
[M-18]+
C27H41O 398.3138 C27H42O2
Unknown
compound H
Specified
degradant-5 0.67
399.3247
[M+H]+
C27H43O2 398.3247 C27H42O2
PCL Active 1.00
399.3256
[M-18]+
C27H43O2 416.3256 C27H44O3
Unknown
compound C
Specified
degradant-6 1.05
458.3638
[M+CH3CN]+
C29H48NO3 416.3638 C27H44O3
Unknown
compounds A
Specified
degradant-7 1.16
433.3313
[M+H]+
C27H45O4 432.3313 C27H44O4
Unknown
compounds D
Specified
degradant-7 1.16
417.3350
[M-18]+
C27H45O3 434.3350 C27H46O4
Unknown
compounds B
Specified
degradant-8 1.12
415.3229
[M-18]+
C27H43O3 432.3229 C27H44O4
353
The probable structures are hypothesized as shown in figure 6.3.5. based on mass spectral
study and based on the chemistry of the PCL molecule and based on elution order in new
method.
354
The HRMS spectra of all above impurities are depicted in figures 6.3.6 to 6.3. 16.
Figure 6.3.6. : HRMS spectra for specified degradant-1 at RRT 0.22:
Figure 6.3.7. HRMS spectra of specified degradant-2 at RRT 0.25.
355
Figure 6.3.8. HRMS spectra of specified degradant-3 at RRT 0.26
Figure 6.3.9 : HRMS spectra of specified degradant-4 at RRT 0.64
356
(USP unknown compound F):
Figure 6.3.10. HRMS spectra of specified degradant-4 at RRT 0.64
(USP unknown compound G):
Figure 6.3.11. HRMS spectra of specified degradant-5 at RRT 0.67
357
(USP unknown compound H)
Figure 6.3.12. HRMS spectra of PCL.
358
Figure 6.3.13. HRMS spectra of specified degradant-6 at RRT 1.05
(USP unknown compound C)
Figure 6.3.14. HRMS spectra of specified degradant-7at RRT 1.16
(USP unknown compound A)
359
Figure 6.3.15. HRMS spectra of specified degradant-7at RRT 1.16
(USP unknown compound D)
Figure 6.3.16. HRMS spectra of specified degradant-8 at RRT 1.12
(USP unknown compound B)
2.3. Method validation
2.3.1. Precision
The precision of test method (intra-day precision) is evaluated by injecting
the neutralized acid stressed sample. Acid stressed sample is injected six times into
the chromatographic condition developed. Relative standard deviations of % of
PCL and its impurities are evaluated. Intra-day precision is also demonstrated for
PCL spiked on placebo matrix at 1% level. Inter day Precision study is conducted
on a different day with different mobile phase, with different HPLC and different
column. Test preparations of sample are prepared similar to intra-day precision and
the Relative standard deviations of % of PCL and its impurities are evaluated. The
% RSD values are presented in table 6.3.5 and 6.3.6. % RSD values of less than
360
15% for PCL and its impurities shows that method is precise and work
satisfactorily on different day, with different column and different HPLC system.
2.3.2. LOQ and LOD
The limit of detection, limit of quantification are determined by following signal
to noise ratio method for PCL diluted standard. A precision study also conducted at
LOQ level for PCL. The results shows that method is sensitive enough to quantify
impurities well below the ICH reporting threshold of 0.1%. The data is summarized in
table 6.3.7.
2.3.3. Linearity
A linear calibration plot for PCL diluted standard is drawn over the calibration
range LOQ to 150% of the specification level of 1.0%. Correlation co-efficient for
PCL is found to be greater than 0.997. The regression analysis results are shown in
table 6.3.8. The results indicates that an excellent correlation exists between the peak
area and concentration of the analyte for PCL. The linearity graphs are presented as
figure 6.3.17.
2.3.4. Accuracy
The percentage recovery of PCL in presence of placebo matrix of PCL capsules
from LOQ to 150% spike level are in the range of 98.8% TO 113.7%. The % recovery
values for PCL are presented in table 6.3.9. The data shows that the method is having
capability to estimate accurately in presence of placebo matrix of PCL capsules
Table 6.3.5: Results of Inter-day precision of test method for PCL and its impurities.
S.No
PCL % of Specified degradant
1 2 3 4 5 6 7
1 0.98 0.46 0.17 0.56 0.58 0.60 ND 0.91
2 0.94 0.47 0.18 0.54 0.59 0.59 ND 0.95
3 0.96 0.42 0.19 0.55 0.58 0.64 ND 0.92
4 0.95 0.48 0.18 0.57 0.60 0.63 ND 0.94
5 0.99 0.46 0.20 0.59 0.62 0.62 ND 0.96
6 0.93 0.50 0.21 0.58 0.63 0.65 ND 0.91
Avg 0.96 0.47 0.19 0.57 0.60 0.62 NA 0.93 %RSD 2.4 5.7 7.8 3.3 3.5 3.7 NA 2.3
361
Table 6.3.6: Results of intra-day precision of test method for PCL and its impurities.
Table 6.3.7: LOD , LOQ data of PCL
Name
LOD
in %
S/N
ratio
LOQ
in %
S/N
ratio
PCL 0.023 3.2 0.071 9.8
Precision at LOQ :
Name of
the Active Sample No. % PCL Mean %RSD
PCL
1 0.085
0.083 3.9
2 0.079
3 0.087
4 0.081
5 0.085
6 0.080
Recovery at LOQ :
Name of the
active
Sample
No.
‘µg PCL
added
‘µg’ PCL
found % Recovery
%
Mean
recovery
PCL
1 0.0016 0.0017 106.3
104.2 2 0.0016 0.0016 100.0
3 0.0016 0.0017 106.3
Sample
No.
PCL
% of specified degradants
1 2 3 4 5 6 7
1 1.01 0.51 0.22 0.45 0.62 0.52 ND 0.88
2 1.05 0.53 0.20 0.49 0.61 0.55 ND 0.92
3 1.09 0.50 0.18 0.50 0.63 0.54 ND 0.91
4 1.06 0.49 0.21 0.51 0.62 0.57 ND 0.93
5 1.04 0.51 0.22 0.53 0.64 0.56 ND 0.95
6 1.05 0.53 0.21 0.54 0.65 0.59 ND 0.92
Avg 1.05 0.51 0.21 0.50 0.63 0.56 NA 0.92 %RSD 2.5 3.1 7.3 6.4 2.3 4.4 NA 2.5
362
Fig.6.3.17: Linearity graph of Paricalcitol.
Table 6.3.8 . Recovery data of PCL from formulation matrix.
S.No Spike level
As % of test conc.
‘µg’ added ‘µg’ found
(recovered) % Recovery
1 50% 0.50% 0.0102 0.0116 113.7
107.8 2 50% 0.50% 0.0102 0.0110 107.8
3 50% 0.50% 0.0102 0.0104 102.0
1 75% 0.75% 0.0150 0.0160 106.7
104.5 2 75% 0.75% 0.0150 0.0154 102.7
3 75% 0.75% 0.0150 0.0156 104.0
1 100% 1.00% 0.0203 0.0214 105.4
105.7 2 100% 1.00% 0.0203 0.0219 107.9
3 100% 1.00% 0.0203 0.0211 103.9
1 125% 1.25% 0.0252 0.0249 98.8
101.2 2 125% 1.25% 0.0252 0.0258 102.4
3 125% 1.25% 0.0252 0.0258 102.4
1 150% 1.50% 0.0305 0.0325 106.6
105.6 2 150% 1.50% 0.0305 0.0323 105.9
3 150% 1.50% 0.0305 0.0318 104.3
y = 1022641.47725 x - 61.69
0
10000
20000
30000
40000
50000
0 0.01 0.02 0.03 0.04 0.05
pea
k a
rea
Concentration in µg/ml
Pericalcitol
R = 0.999
363
2.3.5. Robustness
To determine the robustness of the developed method, experimental conditions are
deliberately altered and the separation between PCL and its impurities and tailing factor for
PCL and its impurities are recorded. The flow rate of the mobile phase is 1.5 ml min-1
. To
study the effect of flow rate on the resolution, flow is changed by 0.2 units from 1.3 to 1.7
ml min-1
. The effect of the column temperature on separation is studied at 25⁰C and 35⁰C
instead of 30⁰C. The effect of the percent organic strength on separation is studied by
varying −10 to +10% while other mobile phase components are held constant.
In all the deliberately varied chromatographic conditions (flow rate, column
temperature and composition of organic solvent), all analytes are adequately resolved and
elution orders remained unchanged. RRT of all the known impurities for all deliberately
varied conditions along with original conditions are summarized in table 6.3.9. The
resolution between all critical pair components is greater than 2.0 and tailing factor for PCL
and its impurities is found to be less than 1.2.
2.3.6. Solution stability and mobile phase stability
The stability of PCL in diluted standard solution is estimated against freshly
prepared standard each time. The similarity factor for standard from initial to 5 days is
found to be within the acceptable limits. PCL test preparation prepared as per test method
is injected at Initial and at different intervals upto 5 days. The difference in % of
individual impurities and % of total impurities are found to be within the limits upto 5 days.
The results are summarized in table 6.3.10.
The stability of mobile phase-A & B on bench top is conducted for a period of
about 5 days. Paricalcitol test preparation prepared as per test method is injected into the
chromatographic conditions developed by preparing the solution freshly each time and by
using the stored mobile phase up to 5 days. The difference in % of individual impurities
and % of total impurities from initial to 5 days is found to be within the limits. The results
are summarized in table 6.3.11. From the above study it is established that the PCL diluted
364
standard is stable up to 2 days on bench top, test preparation of PCL capsules is stable upto
5 days on bench top and mobile phase is stable for a period of 5 days on bench top.
364
Table 6.3.9: Results of robustness study
parameter
RRT of Specified degradants
Spe.Deg 1 Spe.Deg 2 Spe.Deg 3 Spe.Deg 4 Spe.Deg 5 Spe.Deg 6 Spe.Deg 7
1.3 ml/min 0.264 0.294 0.309 0.642 0.673 1.084 1.169
1.5 ml/min 0.221 0.246 0.259 0.636 0.665 1.085 1.181
1.7 ml/min 0.209 0.232 0.244 0.617 0.645 1.071 1.147
27°C 0.23 0.257 0.271 0.637 0.666 1.074 1.152
30°C 0.221 0.246 0.259 0.636 0.665 1.085 1.181
33°C 0.229 0.255 0.268 0.633 0.673 1.075 1.157
M.P A ( ethanol ) 90% 0.27 0.313 0.33 0.69 0.714 1.082 1.172
M.P A ( ethanol )100% 0.221 0.246 0.259 0.636 0.665 1.085 1.181
M.P A ( ethanol )110% 0.234 0.257 0.271 0.622 0.649 1.053 1.113
M.P A (dichloromethane) 90% 0.239 0.268 0.282 0.647 0.674 1.081 1.175
M.P A (dichloromethane)100% 0.221 0.246 0.259 0.636 0.665 1.085 1.181
M.P A (dichloromethane)110% 0.232 0.26 0.273 0.649 0.675 1.085 1.179
M.P B ( ethanol ) 90% 0.226 0.253 0.266 0.63 0.66 1.08 1.165
M.P B ( ethanol )100% 0.221 0.246 0.259 0.636 0.665 1.085 1.181
M.P B ( ethanol )110% 0.258 0.286 0.302 0.645 0.672 1.072 1.137
M.P B (dichloromethane) 90% 0.222 0.244 0.257 0.637 0.662 1.077 1.162
M.P B (dichloromethane)100% 0.221 0.246 0.259 0.636 0.665 1.085 1.181
M.P B (dichloromethane)110% 0.232 0.259 0.273 0.642 0.67 1.074 1.152
M.P B (isopropanol) 90% 0.219 0.243 0.255 0.623 0.652 1.085 1.173
M.P B (isopropanol)100% 0.221 0.246 0.259 0.636 0.665 1.085 1.181
M.P B (isopropanol)110% 0.226 0.251 0.264 0.64 0.668 1.072 1.147
Spe.Deg = Specified degradant
365
Table 6.3.10. Results of solution stability
Duration
In days
% of the impurity of Specified degradants upon storage on bench top.
TI
1 2 3 4 5 6 7 MUI
0 0.0820 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0820
1 0.0640 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0640
3 0.0740 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0740
5 0.0974 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0974
Maximum
difference
from initial
0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.02
MUI =Maximum unknown individual impurity, TI = Total impurities
Table 6.3.11.Results of mobile phase stability on bench top
Duration in
days
% of Specified degradants in Paricalcitol test preparation
TI
1 2 3 4 5 6 7 MUI
0 0.0820 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0820
1 0.0633 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0633
3 0.1123 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.1123
5 0.0829 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0829
Max
difference
from initial
0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.03
MUI =Maximum unknown individual impurity, TI = Total impurities
366
5.3.7. Results of specificity studies
All the placebo and stressed samples prepared are injected into the HPLC system
with photodiode array detector as per the described chromatographic conditions.
Chromatograms of placebo solutions have shown no peaks at the retention time of PCL and
its impurities. This indicates that the excipients used in the formulation do not interfere in
estimation of impurities in PCL capsules.
Degradation is not observed in light exposure or moisture. Significant degradation is
observed in acid, base, water, peroxide and thermal degradation. All degradant peaks are well
resolved from each other and from PCL peak in the chromatograms of all stressed samples.
The chromatograms of the stressed samples are evaluated for peak purity of PCL using
Waters Empower Networking software. For all forced degradation samples, the purity angle
(the weighted average of all spectral contrast angles calculated by comparing all spectra in the
integrated peak against the peak apex spectrum) is found to be less than threshold angle (the
sum of the purity noise angle and solvent angle, the purity noise angles across the integrated
peak) for PCL peak. The details of each impurity formed in each stressed sample is
summarised in table 6.3.12. The stressed samples are subjected to mass balance study by
assaying the samples for PCL content apart from estimating the total impurities. The sum of
total % of impurities and assay is presented as mass balance, which is found to be in the range
of 98.3 to 100.4% for the stressed samples. The data indicates that there is no co-elution of
any degradants in the PCL peak and no impurity which is missing, as the mass balance is
close to 100%. Thus, this method is considered as specific and "Stability indicating”. The
chromatogram and purity plots of all stressed samples are shown in figs 6.3.18 to 6.3.24.
367
Table 6.3.12 : Summary of forced degradation studies
Stress condition
% of Paricalcitol Specified degradants
MUI TI % Assay
Mass
balance
1 2 3 4 5 6 7
Control sample 0.082 ND ND ND ND ND ND ND 0.082 99.8 99.9
Acid stress 0.46 0.17 0.56 0.58 0.60 ND 0.91 0.09 3.40 96.4 99.8
Base stress 2.04 0.52 1.48 ND ND ND ND 0.50 4.65 95.0 99.7
H2O2 stress 0.11 ND 0.11 ND ND ND ND ND 0.26 99.8 100.1
Sunlight stress 0.08 ND ND ND ND ND ND ND 0.08 99.8 99.9
UV light stress 0.07 ND ND ND ND ND ND ND 0.07 100.2 100.3
Thermal stress 1.02 0.29 0.87 ND ND ND ND 0.32 2.55 97.2 99.8
Humidity stress 0.08 ND ND ND ND ND ND ND 0.08 99.7 99.8
TI: Total impurities; MUI = Maximum unknown impurity, ND : Not detected.
368
Fig 6.3.18: Chromatogram and purity plot of acid stressed PCL capsules..
369
Fig 6.3.19: Chromatogram and purity plot of base stressed PCL capsules.
370
Fig 6.3.20: Chromatogram and purity plot of H2O2 stressed PCL capsules.
371
Fig 6.3.21: Chromatogram and purity plot of sun light stressed PCL capsules.
372
Fig 6.3.22: Chromatogram and purity plot of UV light stressed PCL capsules.
373
Fig 6.3.23: Chromatogram and purity plot of heat stressed PCL capsules.
374
Fig 6.3.24: Chromatogram and purity plot of humidity stressed PCL capsules.
375
3. Conclusion:
A precise, sensitive, specific, accurate, validated and well-defined stability indicating
LC method for the determination of degradation products of PCL in oil based capsules
formulation is described. The behavior of PCL under various stress conditions is studied. All
of the degradation products are found to be well separated from each other except those which
are structurally closely related. Although reverse phase USP method gives best separation for
unknown degradants, it is found to be not suitable for oil based formulations. The new
method developed is found to be the best suitable for oil based PCL capsule formulation.
HRMS studies and the elution patterns in normal phase chromatography lend supporting
evidence to the structures proposed for unknown compounds which are declared as unknown
degradants in USP. 3 new thermal degradants are found due this study which are not declared
in literature till date and which are not possible to get detected in USP method. Although
further study is needed to confirm the structures by NMR, this study has given a way forward
approach for structural characterization of degradants of PCL. The information presented in
this study could be very useful for quality monitoring of oil based PCL pharmaceutical dosage
forms and can be used to check drug quality during stability studies.
376
Reference
1. USP Monograph for Paricalcitol and Paricalcitol Injection USP 32 sup 2
2. Raquel, Ortega., Natalia Navasi., J. AOAC Int..,2011;94(2):543-549.
3. Cato, A., Cady, W.W., Soltanek, C., Qasawa, B., Chang, M., Stoll, R., Am. J. Kidney
Dis., 1998; 32: S55–S60
4. Palaparthy, R., Pradhan, R.S., Chan, J., Rieser, M., Chira, T., Galitz, L., Awni, W.,
Williams, L.A., Biopharm. Drug Dispos., 2007; 28: 65–71
5. Perdue, James, D., Seaton, Pamela, J., Tyrell, John, A., DeVido, Daniel, R., J.
Pharm.Biomed.Anal., 2006;41(1):117-123
323
Section (V): Stability Indicating HPLC Assay method for Paricalcitol capsules.
This section reports the various aspects relating to the development and validation of
stability indicating HPLC method for assay of Paricalcitol (PCL) capsules.
1. Experimental
1.1. Chemicals
Samples of PCL API are received from M/s. Formosa laboratories, Taiwan. PCL
Capsules of 1,2 and 4 µg & all excipients are received from formulation R&D, Dr Reddy’s
Laboratories, Hyderabad, India. The HPLC grade dichloromethane, n-Hexane, isopropyl
alcohol, methanol and analytical grade NaOH, HCl, 30% hydrogen peroxide are purchased
from Merck, Darmstadt, Germany. High purity water is prepared by using Millipore Milli-Q
plus purification system.
1.2. Determination of appropriate UV wavelength
The suitable wavelength for the determination of PCL in diluent is identified by scanning
over the range 200–400 nm with a Shimadzu UV-160 (Shimadzu, Japan) double beam
spectrophotometer.
1.3. Instrumentation and chromatographic conditions
The Waters HPLC System with a photo diode array detector is used for the
method development and force degradation studies .The data is monitored and processed
using Waters Empower Networking software. The HPLC system used for method validation
is waters HPLC system with diode array detector and Agilent 1100 series LC system with
variable wavelength detector (VWD). The chromatographic column used is Lichrosphere
Silica 60 , 250 x 4.0 mm, 5µm. The chromatographic condition follows an isocratic elution
with a mobile phase consisting of mixture of n-Hexane, dichloromethane, isopropyl alcohol
and methanol in the ratio of 800:200:120:50 v/v respectively. The flow rate of the mobile
phase is 1.0 ml min-1
. The column temperature is maintained at 40ºC and the detection
wavelength is 252 nm. The injection volume is 400µl.
1.4. Diluent: Dichloromethane is used as diluent.
324
1.5. Preparation of standard drug solution:
The stock solution of PCL USP reference standard (equivalent to about 10 µg. ml-1
of PCL) is prepared in diluent. The working standard solution (0.2 µg ml-1
of PCL) is
obtained by dilution of the stock solution in diluents for sample analysis purpose. The
Specimen chromatograms of diluent and standard are shown in fig.6.2.1.
Fig 6.2.1: Specimen chromatogram of diluent and PCL standard 0.2µg ml-1
.
1.6. Test Preparation for pharmaceutical formulations:
10 capsules of PCL capsules (hardgelatin) are taken and the contents are emptied by
cutting with a sharp blade and then squeezing each capsule without loss of material into a 50
ml beaker. The blade is washed with about 15 ml of diluent into the beaker, contents of the
beaker is then swirled to dissolve in the diluent and mixed. The resultant clear solution is then
Blank
Standard
325
transferred through funnel in to a volumetric flask. (50 ml for 1µg capsules, 100 ml for 2 µg
capsules and 200 ml for 4 µg capsules). The empty shells are then sonicated with adequate
amount of diluent for about 5 minutes and the solvent is then transferred in to the volumetric
flask. The empty shells are washed minimum 3 times with diluent and washings are
transferred in to the same volumetric flask. The contents of the flask is then diluted up to the
volume with diluent and mixed well. The resultant clear solution is used for injection. Placebo
sample is prepared in the same way by taking the placebo equivalent its weight present in a
test preparation. The specimen chromatogram of placebo and test samples is shown in
fig.6.2.2.
Fig 6.2.2: Specimen chromatogram of placebo and PCL Capsules.
1.7. Specificity:
Regulatory guidances in ICH Q2A, Q2B, Q3B and FDA 21 CFR section 211, require the
development and validation of stability-indicating potency of assays. However, the current
guidance documents do not indicate detailed degradation conditions in stress testing. The
forced degradation conditions, stress agent concentration and time of stress, are found to
Placebo
Test sample
326
effect the % degradation. Preferably not more than 20% is recommended for active materials
to make the right assessment of stability indicating nature of the chromatographic methods.
The discovery of such stress conditions which can yield not more than 20% degradation is
based on experimental studies. Chromatographic runs of placebo solution and samples
subjected to force degradation are performed in order to provide an indication of the stability
indicating properties and specificity of the method. The stress conditions employed are acid,
base, neutral and oxidant media, moisture, heat and light. After the degradation treatments are
completed, the samples are allowed to equilibrate to room temperature, neutralized with acid
or base (as necessary), and diluted with diluent to get the working concentrations equivalent
to test preparation. The samples are analyzed against a freshly prepared control sample (with
no degradation treatment) and evaluated for peak purity by using photo diode array detector.
Specific conditions are described below.
1.7.1. Placebo (excipients) interference:
Placebo solutions are prepared by taking the weight of placebo approximately
equivalent to its weight in the sample as described in the test preparation for PCL capsules
dosage form.
1.7.2. Effect of acid, base and peroxide :
PCL capsules medicament equivalent to 10 µg is treated with 1 ml of 0.1N methanolic
HCl, 1 ml of 0.1N methanolic NaOH and 0.1 ml of 6% H2O2 for 90 minutes, 17 hours and 2
hours respectively on bench top with continuous shaking. The resulting solutions are then
diluted to make 50 ml volume with diluents to get the final concentration of drug at about 0.2
µg ml-1
.
1.7.5. Effect of moisture and heat
To evaluate the effect of moisture and heat, PCL capsules medicament is distributed as
thin layer over two glass plates. One plate is then exposed to 25ºC/90% relative humidity for
7 days. Similarly another plate is exposed in an oven at 60ºC for 20 hours. Then, both the
samples are subjected to sample preparation using diluents as described in test preparation.
327
1.7.6. Effect of UV and visible light
To study the photochemical stability of the drug product, the PCL capsules medicament
is exposed to 1200 K Lux hours of visible light and 200 Watt hours/ m2 of UV light by using
photo stability chamber. After exposure the samples are subjected to sample preparation using
diluent as described in test preparation.
1.8. Method validation
1.8.1. Precision
The precision (intra-day precision) of test method is evaluated by assaying the six
different individual preparation of the PCL Capsules 1µg, 2µg and 4µg respectively and
analyzed as per test method. The % assay is calculated against USP reference standard and the
relative standard deviation of six different assays of PCL is then calculated. The intermediate
precision (inter day precision) of the method is also evaluated using two different HPLC
systems and different HPLC columns in different days in the same laboratory.
1.8.2. Linearity
Linearity study for assay method is made using six different concentration levels in
the range of about 0.02- 0.4µg ml-1
of PCL (corresponding to 10 to 200% of assay of nominal
sample concentration of 0.2 µg ml-1
). The
data of peak area versus concentration is subjected
to least-square regression analysis.
1.8.3. Accuracy
A study of recovery of PCL from placebo matrix is conducted. Medicament equivalent
to about 1,2,5,7.5, 10, 12.5 and 15 µg is taken into 50 ml volumetric flask. The medicament
is then dissolved and diluted to obtain test preparation equivalent to about 10%, 20%, 50%,
75%, 100%, 125% and 150% of the target assay concentration (0.2 µg ml-1
) of the PCL
capsules. Sample solutions are prepared in triplicate for each spike level and assayed as per
test method. The % recovery is then calculated.
1.8.4. Robustness
To determine the robustness of the developed method, experimental conditions are
purposely altered one after the other to estimate their effect. Five replicate injections of
standard solution are injected under each parameter change. The effect of flow rate, pH,
column temperature and organic phase composition in mobile phase (dichloromethane,
isopropyl alcohol and methanol) on the tailing factor, theoretical plates of PCL peak and the
328
%RSD for peak areas of replicate injections of standard is studied at flow rates of 0.8 ml min-1
and 1.2 ml min-1
, at column temperatures of 35ºC and 45ºC and organic phase compositions
in mobile phase at + 10% respectively.
1.8.5. Solution stability and mobile phase stability
The solution stability of PCL in the assay method is carried out by leaving solutions of
both the test preparation and reference standard preparation in tightly capped volumetric
flasks at room temperature for 5 days. The same sample solutions is assayed periodically
during the study period.
The mobile phase stability is also carried out by assaying freshly prepared sample
solutions against freshly prepared reference standard solutions at periodic interval for 5days.
Mobile phase prepared is kept constant during the study period. The % RSD of assay of PCL
is calculated for the study period during mobile phase stability and solution stability
experiments.
2. Results and discussion
2.1. Determination of suitable wavelength
The UV spectrum of PCL recorded in the range 200-400 nm is illustrated in fig.6.2.3.
The spectrum indicates that 252 nm gives a good sensitivity for the assay.
Fig 6.2.3: UV Spectra of paricalcitol.
329
2.2. Optimization of chromatographic conditions
The HPLC procedure is optimized with a view to develop a stability
indicating assay method for estimation of PCL in oil based capsules formulation. PCL
assay method is available in USP for PCL Injection. To develop the assay method for PCL
based formulation, where in medicament liquid is filled into hard gelatin capsules and
sealed, initially attempts were made by using reverse phase chromatographic conditions of
the USP PCL injection method. PCL capsules formulations are of very low dose, namely
1 µg, 2 µg and 4 µg per capsule. Due to very low concentration of the drug present in the
medicament, it is observed that a very high injection volume is necessary. A minimum of
400µl injection volume is selected to get adequate method sensitivity. Preliminary
experiments are conducted to dissolve the excipients (mainly medium chain triglycerides
and Cremophore EL) in acetonitrile. When placebo and medicaments are dissolved in
acetonitrile, it is observed that all placebo components are not going into solution and
some of excipients are found to be immiscible. The recovery of PCL analyte is found
satisfactory in acetonitrile, but due to presence of Cremophore EL in formulation,
inconsistency of peaks is observed due to excipient immiscibility in acetonitrile. Several
experiments are conducted to separate out the excipients peaks from PCL by modifying
the USP method gradient program and by changing the column, but without much
success, due to inconsistency of placebo peaks. Studies revealed that the excipient majorly
responsible for interference is Cremophor EL. Therefore, studies were conducted based on
the reported literature method [5] to remove the Cremophor EL from formulation by using
precipitation technique involving mercuric chloride in a reaction with Cremophor EL to
form an insoluble complex in ethanol. The efforts made to remove the cremophore EL
from formulation based on above mentioned literature method are successful, but PCL is
getting degraded during sample preparation. Based on the above studies, it was felt
necessary to change the chromatographic method from reverse phase to Normal phase.
This is to resolve the main constraint of excipient solubility and immiscibility with most
of the polar solvents, as normal phase chromatography allows use non polar solvents as
diluents, where in medium chain triglycerides and Cremophore EL are completely soluble.
330
Additionally, due to polarity reversal, interference due to Cremophore EL can be easily
avoided, as it elutes early in normal phase due to its non polar nature.
Studies are conducted using 250 x 4.6mm, silica column by changing the
selectivity of the mobile phase to achieve symmetrical peak shapes and adequate
separation of all degradants and excipient peaks. It is noticed that isocratic elution
methods is suitable. Therefore, experiments are conducted with different combination of
solvents as mobile phase.
Finally a mixture of n-Hexane, dichloro methane, isopropyl alcohol and methanol in
the ratio of 800:200:120:50 v/v respectively as mobile phase was found suitable with
adequate separation of all degradant peaks and avoiding interference from placebo within a
run time of 17 minutes. Optimum flow rate and column temperatures are found be at 1.0 ml
min-1
and at 40ºC respectively.
2.3. Method validation
2.3.1. Precision
Method repeatability (intra-day precision) is evaluated by assaying six samples,
prepared as described in the test preparation. The mean % assay values are found to be in the
range of 100.3 to 102.0 and % RSD for assay values are found to be in the range of 0.4 to 0.8
These are well with in the acceptance criteria i.e. mean % assay between 97.0 -103.0 and RSD
not more than 2.0 %. The intermediate precision (inter day precision) is performed by
assaying six samples on different HPLC systems and different HPLC columns in different
days as described in the sample preparation. The mean % assay values are found to be in the
range of 99.2 to 103.0 and % RSD for assay values are found to be in the range of 1.0 to 1.4.
The result shows good precision of the method (table 6.2.1 and 6.2.2).
331
Table 6.2.1: Results of precision (intra-day) of test method
Sample No.
Intra-day precision
Assay of PCL as % of labeled amount
For 1 µg capsules For 2 µg capsules For 4 µg capsules
1 102.0 100.5 101.8
2 100.3 101.2 101.4
3 102.0 101.4 101.3
4 100.5 100.8 100.5
5 101.8 101.1 102.0
6 100.4 100.4 101.0
Range 100.3 to 102.0 100.4 to 101.4 100.5 to 102.0
Mean 101.2 100.9 101.3
%RSD 0.8 0.4 0.5
Table 6.2.2: Results of precision (inter-day) of test method
Sample No.
Intra-day precision
Assay of PCL as % of labeled amount
For 1 µg capsules For 2 µg capsules For 4 µg capsules
1 102.1 101.3 101.8
2 101.6 101.8 99.2
3 99.5 101.4 100.9
4 100.1 102.1 103.0
5 100.6 101.1 102.6
6 101.3 99.2 102.9
Range 99.5-102.1 99.2-102.1 99.2-103.0
Mean 100.9 101.2 101.7
%RSD 1.0 1.0 1.4
2.3.2. LOQ and LOD
The LOQ and LOD are determined based on signal-to-noise ratios at analytical
responses of 10 and 3 times the background noise, respectively. The LOQ is found to be
0.01 μg ml -1
with a resultant %RSD of 4.6(n = 5). The LOD is found to be 0.003 μg ml.-1
2.3.3. Linearity
A linear calibration plot for assay of PCL is obtained over the calibration range 0.02-
0.4 µg ml-1
and the correlation co-efficient is found to be 1.000. The result shown in fig.6.2.4
indicates that an excellent correlation exists between the peak area and concentration of the
analyte.
332
Fig.6.2.4: Linearity of detector response graph
2.3.4. Accuracy
The percentage recovery of PCL in pharmaceutical dosage form of capsules is shown
in table 6.2.3 ranged from 97.4 to 100.9 and indicates high accuracy of the method.
Table 6.2.3: Recovery results of PCL.
Sample
No.
Spike
level
“µg/ml”
added
“µg/ml”
found
%
Recovery
Mean %
Recovery
1 10% 0.0203 0.0201 99.2
98.6 2 10% 0.0203 0.0201 99.2
3 10% 0.0203 0.0198 97.4
1 20% 0.0406 0.0404 99.5
99.4 2 20% 0.0406 0.0403 99.3
3 20% 0.0406 0.0404 99.5
1 50% 0.1016 0.1005 98.9
99.5 2 50% 0.1016 0.1011 99.5
3 50% 0.1016 0.1018 100.2
1 75% 0.1524 0.1519 99.7
100.1 2 75% 0.1524 0.1529 100.3
3 75% 0.1524 0.1528 100.3
1 100% 0.2032 0.2046 100.7
100.2 2 100% 0.2032 0.2027 99.8
3 100% 0.2032 0.2036 100.2
1 125% 0.2540 0.2540 100.0
100.2 2 125% 0.2540 0.2529 99.6
3 125% 0.2540 0.2563 100.9
1 150% 0.3048 0.3011 98.8
100.0 2 150% 0.3048 0.3073 100.8
3 150% 0.3048 0.3064 100.5
333
2.3.5. Robustness
In all the deliberately varied chromatographic conditions studied (flow rate, column
temperature, organic composition in mobile phase), the tailing factor, theoretical plates and
the % RSD for the PCL peak area for five replicate injections of standard is found to be
within the acceptable limit of not more than 2.0%, illustrating the robustness of the method
(table 6.2.4).
Table 6.2.4: Results of robustness study
Parameter
Observed value
Variation Tailing factor Theoretical
plates
%RSD
1.Flow rate 0.8 ml min-1 1.1 7326 1.5
1.0 ml min-1 1.1 6220 0.6
1.2 ml min-1 1.0 5371 0.9
2.Column temperature 35ºC 1.1 5447 0.3
40ºC 1.1 6220 0.6
45ºC 1.1 6253 0.3
3.Mobile phase (for
dichloromethane)
90% 1.1 5885 0.4
100% 1.1 6220 0.6
110% 1.1 5983 0.4
4. Mobile phase
(for IPA)
90% 1.1 7380 0.2
100% 1.1 7193 0.5
110% 1.1 6924 1.2
5. Mobile phase
(for methanol)
90% 1.1 7045 0.3
100% 1.1 6974 0.4
110% 1.1 7437 0.4
2.3.6. Solution stability and mobile phase stability
The difference in % assay of PCL test and standard preparations upon storage on
bench top is found to be less than 1.6% up to 5 days. Mobile phase stability experiments
showed that tailing factor and % RSD are less than 1.1and 0.5% respectively and theoretical
plates are more than 5914 up to 5days. The solution stability and mobile phase stability
experimental data confirms that standard and test preparations and mobile phase used during
assay determination are stable up to 5 days.
334
2.3.7. Results of specificity studies
All the placebo and stressed samples prepared are injected into the HPLC system
with photodiode array detector as per the described chromatographic
conditions.Chromatograms of placebo solutions have shown no peaks at the retention time of
PCL. This indicates that the excipients used in the formulation do not interfere in estimation
of PCL in capsules formulation dosage form.
Degradation is not found to be significant when exposed to light and humidity. In acid
hydrolysis, base hydrolysis, thermal stress and oxidative studies, significant degradation is
observed. All degradant peaks are well resolved from PCL peak in the chromatograms of all
stressed samples. The chromatograms of the stressed samples are evaluated for peak purity of
PCL using Waters Empower Networking software. For all forced degradation samples, the
purity angle (the weighted average of all spectral contrast angles calculated by comparing all
spectra in the integrated peak against the peak apex spectrum) is found to be less than
threshold angle (the sum of the purity noise angle and solvent angle, the purity noise angles
across the integrated peak) for PCL peak (table 6.2.5). This indicates that there is no
interference from degradants in quantitating the PCL in capsules dosage form. Thus, this
method is considered "Stability indicating”. The typical chromatogram and purity plots of all
stressed samples are shown in figs 6.2.5 to 6.2.11.
Table 6.2.5: Table of results of specificity
Stress condition % Assay Purity
Angle
Purity
Threshold
Stressed with 0.1 N methanolic HCl for about
90 min on bench top 96.2 2.437 5.235
Stressed with 0.1 N methanolic NaOH for
about 17 hours on bench top 98.4 0.857 1.083
Stressed with 6% H2O2 in methanol for about
2 hours on bench top 95.5 0.786 1.040
Exposed to Sunlight for 1.2 million Lux hours
in photo stability chamber 100.2 0.780 1.001
Exposed to UV light for 200watt hours/square
meter in photo stability chamber 100.3 0.778 0.967
Heated at 60° C for about 20 hrs in oven 98.3 0.801 1.072
Exposed to humidity at 25°C, 90% RH for
about 7 days 100.1 0.782 1.007
335
Fig 6.3.5: Chromatogram and purity plot of acid stressed PCL capsules.
Fig 6.3.6: Chromatogram and purity plot of base stressed PCL capsules.
336
Fig 6.3.7: Chromatogram and purity plot of H2O2 stressed PCL Capsules.
Fig 6.3.8: Chromatogram and purity plot of sun light stressed PCL capsules.
337
Fig 6.3.9: Chromatogram and purity plot of UV light stressed PCL capsules.
Fig 6.3.10: Chromatogram and purity plot of thermal stressed PCL capsules.
338
Fig 6.3.11: Chromatogram and purity plot of humidity stressed PCL capsules.
3. Conclusion:
A validated stability-indicating HPLC analytical method has been developed for the
determination of PCL oil based formulation in capsules dosage form. The results of stress
reveal that the method is selective and stability-indicating. The proposed method is simple,
accurate, precise, specific and has the ability to separate the drug from degradation products
and excipients of capsules dosage form. The method is suitable for the routine analysis of
PCL in either bulk powder or in other pharmaceutical dosage forms. The HPLC procedure can
be applied to the analysis of samples obtained during accelerated stability experiments to
predict the expiry dates of PCL in bulk and in formulations.
top related